Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New published data - prostate cancer

02.02.2006


New published data show that bicalutamide (Casodex) 150mg plus radiotherapy significantly extends survival in men with locally advanced prostate cancer compared to radiotherapy alone



New data published in the February 2006 edition of the British Journal of Urology International (BJUI) confirm that bicalutamide 150mg improves the chance of survival by 35 per cent (hazard ratio = 0.65; 95% CI = 0.44 to 0.95, p = 0.03)1 in men with locally advanced prostate cancer (when the disease has spread into the capsule of the prostate or through the prostate into the surrounding tissue) when given bicalutamide 150mg as adjuvant to radiotherapy compared to radiotherapy alone. Bicalutamide 150mg is the only anti-androgen for which this has been shown.1

Also the data from the largest ever treatment study in prostate cancer show that in locally advanced disease, bicalutamide 150mg adjuvant to radiotherapy or radical prostatectomy reduces the risk of disease progression by 31 per cent (hazard ratio = 0.69; 95% CI = 0.58 to 0.82, p < 0.001) leading to a significant survival benefit of 35 per cent when used as adjuvant to radiotherapy.1, In addition, in men with locally advanced prostate cancer, when bicalutamide 150mg was given as monotherapy (alone) there was a 40 per cent reduction in risk, which extended survival free of progression by a median of 2.9 years, showing a trend towards improved survival.2


Commenting on the data, Dr Heather Payne, Consultant in Clinical Oncology, Middlesex Hospital, London stated: "A diagnosis of prostate cancer is truly devastating for the patient. A treatment that both extends a patient’s life and delays the recurrence of the disease whilst maintaining a man’s quality of life is the ultimate goal when managing this condition. This new data from the EPC Trial Programme demonstrates that bicalutamide 150mg meets these vital needs and will have this effect for men with locally advanced prostate cancer."

Results also confirm that treatment with bicalutamide 150mg significantly reduces the risk of bone metastases by 36 per cent in men with locally advanced prostate cancer compared to watchful waiting and by 23 per cent when added to radiotherapy or radical prostatectomy alone.2 Bone metastases are a symptom of disease progression and can include bone and back pain that can cause difficulty in walking and carrying out other daily activities and in more advanced cases can lead to spinal cord compression. By delaying disease progression, bicalutamide 150mg helps men with locally advanced prostate cancer to maintain an active lifestyle.

Patients with locally advanced prostate cancer have a significant risk of their disease progressing, seriously impacting quality of life. Therefore, therapies that improve progression-free survival whilst allowing patients to maintain a normal lifestyle are vital in managing the disease. In addition to improving progression-free survival, bicalutamide 150mg alone demonstrates equal efficacy to castration and provides patients with significant quality of life benefits. Compared with castration, bicalutamide 150mg provides better maintenance of physical capacity and sexual interest.3, Bicalutamide 150mg also maintains bone mineral density, which is lost with castration and is associated with an increased risk of fractures.

The EPC Trial Programme has followed 8,113 patients for an average of 7.4 years in 23 different countries. Patients will continue to be followed up for both disease progression and survival for a minimum period of 10 years after the last patient was enrolled into the study. The 3rd Analysis of the EPC Programme gives additional confirmation that bicalutamide 150mg is a proven treatment option for men with locally advanced prostate cancer delaying disease progression.

In the UK, bicalutamide (Casodex) 150 mg is indicated for patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO). Bicalutamide (Casodex) 150mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Bicalutamide (Casodex) 150mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Rosie Allan | alfa
Further information:
http://www.bjui.org
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>